Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
Kate Hermans has taken over the reins of Ambrx Biopharma Inc (NASDAQ:AMAM) as interim CEO following the abrupt departure of Feng Tian,…
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Looking At Bristol-Myers Squibb’s Recent Whale Trades
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Analyzing Bristol-Myers Squibb’s Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 29.89% since its last report. The company recently reported that it has 27.33 million shares sold short, which is 1.29% of all regular shares that are available for trading.
Recap Of Friday’s Biotech Catalysts – End of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
Bristol-Myers Squibb’s Return On Capital Employed Overview
According to Benzinga Pro, during Q2, Bristol-Myers Squibb (NYSE:BMY) earned $1.43 billion, a 11.38% increase from the preceding quarter. Bristol-Myers Squibb also posted a total of $11.89 billion in sales, a 2.05% increase since Q1.
Earnings Scheduled For July 27, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.